Taking Two or More Blood Pressure Medicines? How Trials Work
Needing more than one blood pressure medicine is not a sign that you have failed. For many adults it is the standard approach. The 2025 AHA and ACC guideline actually prefers starting with two medicines, often in a single combined pill, for people with stage 2 hypertension. The harder question comes when two or three medicines still do not bring your numbers to goal.
Key takeaways
Combining medicines from different classes is a normal, guideline-backed way to treat high blood pressure.
A diuretic (“water pill”) is part of many combinations, and it is one of the criteria in the ZENITH study.
Clinical trials follow strict rules: independent ethics review, informed consent and the freedom to leave at any time.
In a placebo-controlled trial such as ZENITH, some participants receive placebo, and everyone keeps their usual medicines.
Why doctors combine blood pressure medicines
Blood pressure is controlled by several systems at once: how much fluid your kidneys hold on to, how tightly your blood vessels squeeze, and hormones that signal both. Each class of medicine targets a different part of that system, so two lower-dose medicines often work better than one medicine at a high dose, with fewer side effects.
Diuretics ("water pills") help the kidneys remove extra salt and water. Examples include hydrochlorothiazide (HCTZ), chlorthalidone, indapamide and furosemide.
ACE inhibitors block a hormone step that narrows blood vessels. Examples include lisinopril, enalapril and ramipril.
ARBs block the same hormone pathway at a different point. Examples include losartan, valsartan and olmesartan.
Calcium channel blockers relax the muscle in artery walls. Examples include amlodipine and nifedipine.
Not sure whether one of your medicines is a diuretic? Check the label or ask your pharmacist. It is a quick question that matters for many research studies, including the one described below.
What a clinical trial is, in plain terms
A clinical trial is a carefully planned study that tests whether a medicine or approach is safe and whether it works. Before any trial can enroll people in the U.S., an independent ethics committee called an Institutional Review Board (IRB) must review and approve it.
Phase 1 asks whether a medicine is safe and what dose makes sense. It usually involves dozens of people.
Phase 2 asks whether it seems to work and what side effects appear, usually in hundreds of people.
Phase 3 asks whether it works better than, or adds to, what is already available, in hundreds to thousands of people. ZENITH is a Phase 3 study.
Words you will hear during screening
Randomization: a computer assigns you to a group by chance, like a coin toss. Neither you nor your doctor chooses.
Placebo: a look-alike injection or pill with no active medicine. Comparing against placebo is how researchers tell a real effect from chance.
Double-blind: neither you nor the study staff know which group you are in until the study ends, which keeps results fair.
Informed consent: a written explanation of the study's purpose, visits, possible risks and your rights. You can ask questions, take it home and change your mind at any time.
On two or more blood pressure medicines, including a water pill? See whether ZENITH may be a fit.
The ZENITH study, explained
ZENITH (NCT07181109) is a Phase 3 trial of zilebesiran, an investigational medicine given as an injection under the skin every six months. It is designed to reduce the liver's production of angiotensinogen, a protein that feeds into one of the body's main blood-pressure-raising pathways. In the study, zilebesiran or placebo is added to the blood pressure medicines participants already take.
Study snapshot: ZENITH (NCT07181109)
What is being studied
Zilebesiran, an investigational medicine given as an injection under the skin every six months, added to a person's usual blood pressure medicines.
Compared with
Placebo (an injection with no active medicine). Participants keep taking their regular blood pressure medicines either way.
Main question
Whether zilebesiran lowers the risk of serious heart and blood vessel events, such as heart attack, stroke, heart failure events or death from cardiovascular causes.
Size and scope
A global Phase 3 study planned to include about 11,000 adults in 35 countries.
Who may be a fit
Adults whose blood pressure stays high despite two or more blood pressure medicines, and who have established cardiovascular disease or high cardiovascular risk.
Local study sites
Research sites working with HEKMA include Birmingham, AL; Evansville, IN; Phoenix, AZ; and San Antonio, TX.
The criteria are specific. You can read the full picture of who may be a fit, and common reasons someone may not be, in our overview of blood pressure that stays high on medication.
Weighing it up honestly
A trial is a personal decision, and it helps to look at both sides before you start.
What people often value
Contributing to research that could shape future care for people with hard-to-control blood pressure
Scheduled study visits where your health is checked according to the study plan
Clear written information about every step before you agree
What to think through
You may receive placebo rather than the study medicine
Investigational medicines can have side effects, including ones not yet known
Study visits and tests take time over months or years
Ask the study team anything that matters to you: how often visits happen, what tests are involved, how travel works and who to call with concerns. A good study team welcomes these questions.
Keep taking your medicine
Do not change or stop your blood pressure medicines because of anything you read here. Talk with your healthcare professional first.
Frequently asked questions
Is it bad to need several blood pressure medicines?
No. Combining medicines from different classes is a standard, guideline-recommended way to treat high blood pressure. It reflects how many body systems control blood pressure.
What does placebo-controlled mean?
Some participants receive a look-alike treatment with no active medicine. Comparing the groups shows whether the investigational medicine has a real effect. In ZENITH, all participants keep taking their usual blood pressure medicines.
Who protects participants in a clinical trial?
In the U.S., an Institutional Review Board must approve a trial before it starts and continues to oversee it. You also receive an informed consent form and may leave the study at any time.
How is zilebesiran given in the ZENITH study?
Zilebesiran is an investigational medicine given as an injection under the skin every six months in the study. Its safety and effectiveness for this use are still being studied.